Helix Biopharma - Dividend History | HBPCF
Historical dividend payout and yield for Helix Biopharma (HBPCF) since 1971. The current TTM dividend payout for Helix Biopharma (HBPCF) as of December 31, 1969 is $0.00. The current dividend yield for Helix Biopharma as of December 31, 1969 is 0.00%.
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.032B |
$0.000B |
|
Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. Its primary drug candidate is L-DOS47, which is intended for the treatment of inoperable, locally advanced, recurrent, or metastatic non-small cell lung cancer. The Company's product development initiatives are focused primarily on technologies that modulate the tumor microenvironment. It's technology platform, DOS47 yielded approximately two drug product candidates, L-DOS47 and vDOS47. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. L-DOS47 is under clinical study for the treatment of non-small cell lung cancer (NSCLC). L-DOS47 has completed preclinical testing and manufacturing development, following which, regulatory approvals are obtained in Poland and the United States to conduct Phase I/II and Phase I clinical studies. V-DOS47 is an antibody DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor (VEGFR2).
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
